Clinical Trials Logo

Glucose Intolerance clinical trials

View clinical trials related to Glucose Intolerance.

Filter by:

NCT ID: NCT05290506 Completed - Type 2 Diabetes Clinical Trials

Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

Start date: August 1, 2020
Phase: Phase 3
Study type: Interventional

There are studies that suggest glycemic response to incretin-based therapies differs between Asians and Caucasians, whereby Asians have better response compared to Caucasians. Hence, the therapeutic response could also be augmented by difference in incretin system among various ethnicities. This study is carried out to study the effect of dipeptidyl-peptidase IV (DPPIV) inhibitors in prediabetes and T2DM patients who have different levels of GLP-1 and to determine the effect on glycemic profiles, insulin resistance/sensitivity, beta-cell functon.

NCT ID: NCT05215210 Completed - Clinical trials for Impaired Glucose Tolerance

The Effect of Long-term Momordica Charantia Supplementation on Blood Glucose Levels

Bitter-Zoet 2
Start date: March 23, 2022
Phase: N/A
Study type: Interventional

The study is a parallel, double blind, controlled trial in which study participants will receive a 12-week intervention with 3.6 g/d dried bitter-gourd supplements or a reference intervention with 3.6 g/d dried cucumber supplements. Research subjects will come to the research facility for a test day on four occasions, with an interval of 4 weeks. The main study parameter is fasting levels of plasma glucose.

NCT ID: NCT05199636 Completed - Blood Pressure Clinical Trials

Effect of Dragon Fruit Consumption in Individuals at Risk of Type 2 Diabetes

Start date: January 20, 2022
Phase: N/A
Study type: Interventional

In this project, an edible product based on dragon fruit will be tested to determine its effect on blood glucose levels and blood pressure in individuals at risk of type 2 diabetes. The effect of a product from dragon fruit on fasting plasma glucose and blood pressure will be assessed by a parallel study design with two groups and 16 participants in each one. Secondary outcomes such as inflammation biomarkers, lipid profile and oxidative stress markers also will be determined in blood samples.

NCT ID: NCT05181514 Completed - Clinical trials for Hypertriglyceridemia

Impact of Plasma Lipids on β Cell Function and Insulin Sensitivity

Start date: April 30, 2019
Phase: N/A
Study type: Interventional

The investigators aim to evaluate whether and to what extent glucose tolerance, beta cell function, insulin clearance, and glucose metabolic fluxes change in response to an acute increase in plasma triglycerides during lipid infusion, independently of free fatty acid (FFA) levels, in nondiabetic subjects.

NCT ID: NCT05055219 Completed - PreDiabetes Clinical Trials

Conventional and Metabolomic Predictors of Prediabetes & Insulin Resistance

Start date: June 2015
Phase:
Study type: Observational

The purpose of this study is to evaluate the longitudinal test performance of an array of conventional biomarkers of glycemia, including Hemoglobin A1c (HbA1c), and novel metabolomic biomarkers for identifying progression of glucose tolerance (normal to prediabetes or prediabetes to diabetes) in an overweight and obese pediatric cohort.

NCT ID: NCT05035966 Completed - PreDiabetes Clinical Trials

Association of β-amyloid 40 and 42 With Prediabetes

Start date: January 1, 2012
Phase:
Study type: Observational

Background: Previous epidemiological and animal studies have suggested a strong relationship between prediabetes and Alzheimer's disease. Recently, we demonstrated that plasma β-amyloid (Aβ), a potential biomarker for Alzheimer's disease, was elevated in individuals with type 2 diabetes. However, few studies have investigated the associations of plasma Aβ40 and Aβ42 concentrations with prediabetes. Objective: we aimed to investigate the associations of plasma Aβ40 and Aβ42 concentrations with risk of prediabetes in two independent studies. Design: We performed a case-control study and a nested case-control study within a prospective cohort study. In the case-control study, we included 571 newly diagnosed individuals with prediabetes and 571 control participants. Prediabetes individuals were consecutively recruited from subjects who attended the outpatient clinics of Department of Endocrinology at Tongji Medical College Hospital from 2012 to 2015. Concomitantly, we recruited healthy controls from a general population undergoing a routine health checkup in the same hospital. One healthy control was selected at random for each prediabetes individuals according to age (±3 years) and sex. The inclusion criteria of participants were as follows: age ≥30 and ≤80 years, BMI <40 kg/m2, no history of prediabetes and diabetes mellitus, no history of receiving pharmacological treatment for hyperlipidemia, nor any clinically systemic disease, any acute illness, and chronic inflammatory or any infective disease. An independent nested case-control study was conducted within an ongoing cohort study, namely the Tongji-Ezhou cohort. Briefly, 5533 participants, including 3101 retired employees and 2432 working employees, were enrolled from Echeng Stell and received healthcare for a baseline investigation between 2013 and 2015. The first follow-up for all participants was finished by mid-2020. Considering the low incidence of prediabetes among young working employees, we performed the nested case-control study among retired employees. During the follow-up, 119 new-onset prediabetes cases were diagnosed within the retired employees according to fasting plasma glucose. We randomly selected the control participants who matched 2:1 to the cases by age (±3 years) and sex from the retired employees with normal fasting plasma glucose. The inclusion criteria were the same as the case-control study; 2 new-onset prediabetes cases aged >80 years were excluded. Additionally, 17 cases without enough plasma were excluded. Finally, 100 individuals with new-onset prediabetes and 200 well-matched control participants were included for the analysis of the nested case-control study. These two studies were approved by the Ethics and Human Subject Committee of Tongji Medical College. All enrolled participants in the two studies were of Chinese Han ethnicity and provided informed written consent. Plasma Aβ40 and Aβ42 concentrations were simultaneously measured by validated assay platforms from Meso Scale Discovery (MSD; Rockville, MD, USA).

NCT ID: NCT04892186 Completed - Clinical trials for Polycystic Ovary Syndrome

Effects of Myo-inositol in Women With Polycystic Ovary Syndrome

Start date: March 26, 2021
Phase: N/A
Study type: Interventional

The study will be carried out at the hospital of the medical school of sao paulo (HC-FMUSP) and the goal is to compare the effects of the administration of myo-inositol in relation to the effects of metformin in women with Polycystic Ovary Syndrome and insulin resistance or glucose intolerance. Menstrual cycle, hyperandrogenism, chronic inflammatory process, carbohydrate metabolism, hepatic steatosis will be evaluated. In total, 60 women in the reproductive period, with a variable age between 18 and 36 years old will be recruited and randomized in two groups: intervention- myo-inositol for 6 months, control group will use metformin also for 6 months.

NCT ID: NCT04881890 Completed - PreDiabetes Clinical Trials

Low-Carbohydrate Diabetes Prevention Program Among Veterans With Prediabetes

VA LC-DPP
Start date: October 5, 2020
Phase: N/A
Study type: Interventional

The investigators will conduct a single-arm mixed methods pilot study to examine the feasibility and acceptability of a low-carbohydrate diabetes prevention program (LC-DPP). The investigators will estimate weight loss as well as the percentage of participants who achieve 5% body weight loss at 6 month and 12 month timepoints. Weight loss from the pilot VA LC-DPP cohort will be compared to weight loss outcomes from previously published DPP studies and the VA MOVE! program. The investigators will also evaluate secondary outcomes including change in physical activity, mental health, psychosocial functioning, and hemoglobin A1c over the 12-month study period. The investigators will also conduct qualitative interviews with participants at 6 and 12 months.

NCT ID: NCT04863313 Completed - Clinical trials for Overweight and Obesity

Effect of a Probiotic on the Glycemic Profile and the Fecal Microbiota of Prediabetic Subjects (PREDIABETCARE)

PREDIABETCAR
Start date: March 11, 2021
Phase: N/A
Study type: Interventional

According to the data from the Di@bet.es study, which is part of the National Diabetes Strategy, the prevalence of type 2 diabetes among Spanish population is 13.8%. Diabetic patients suffer from several short and long term complications, which are related to a significant worsen of quality of life and a substantial increase in death rate. In this sense, it is important to prevent the development of Type 2 diabetes. Therefore, it is of high relevance to identify and to treat prediabetic subjects prior to the development of the disease. Many strategies have been implemented to reverse this situation, such as changes in diet and lifestyle, among others. However, it is hard to achieve changes in lifestyle and despite the use of some drugs in this phase of the disease, the problem continues growing. For this reason, new strategies to combat the development of type 2 diabetes are been investigated, such as the use of probiotic formulations. However, at the moment, few studies evidence the effect of probiotics on glycemic regulation. Therefore, an interesting opportunity arises according to the potential ability of probiotic formulation for the control of prediabetes. Considering this background, the main objective of this research is to assess the effect of a new probiotic formulation on glycemic control, insulin resistance and the composition of the fecal microbiota in prediabetic subjects.

NCT ID: NCT04812392 Completed - Clinical trials for Cardiovascular Diseases

Physical Inactivity Impacts on Blood Vessel Health and Glucose Levels in an Aging Population

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Physical inactivity is known to increase post meal blood sugar levels in young, active populations. However, how quickly this may occur in active, older adults is not clear. Further, the relationship between blood vessel health and blood sugar disturbances which occur to acute physical inactivity is not clear. It is unknown if impairments in blood vessel function precede increases in blood sugar levels that occurs with inactivity in an aging population. This study aims to determine if short term reductions in physical activity impair blood vessel health and blood glucose control to a greater extent in an aging population compared to a young population. The investigators hypothesize that 3 days of reduced physical activity will result in impaired blood vessel function and glycemic control in an aged population.